ISTH 2022 – Novo moves forward with its Hemlibra rival | Evaluate
fc>2021</fc> clinical trials update: Innovations in hemophilia therapy
A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice - ScienceDirect
Mim8 is associated with improved thrombin generation vs. emicizumab in patients with haemophilia A, with and without inhibitors - ISTH Congress Abstracts
A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice - ScienceDirect
Mim8 - a Next-Generation FVIII Mimetic Bi-Specific Antibody - Potently Restores the Hemostatic Capacity in Hemophilia a Settings in Vitro and In Vivo - ScienceDirect
Novo Nordisk A/S: Mim8 phase 1 & 2 data demonstrates
Novo's attempt to snatch Roche's hemophilia crown gets serious
Summer 2022 haemophilia trial update - European Pharmaceutical Review
Novo Nordisk grows GLP-1 market share in Q2 in the US with Ozempic® and Rybelsus® - MidgardFinance.com
Mim8 data sees potential as once monthly treatment for haemophilia A - European Pharmaceutical Manufacturer
A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice - ScienceDirect
Mette Loftager's research works | Novo Nordisk, Copenhagen and other places
Hemophilia Clinical Research Trials | CenterWatch
Novo Nordisk prepares phase III trial of potential blockbuster drug — MedWatch
Novo Nordisk's Mim8 Shows Potential As Once Monthly Treatment For Hemophilia A
Novo Nordisk outlines strategy for revamped rare diseases unit | BioWorld
Emerging drugs for hemophilia A: insights into phase II and III clinical trials
A Novel Next-Generation FVIII Mimetic, Mim8, Has a Favourable Safety Profile. Results from a 26-Week Safety Study in Cynomolgus Monkeys - ScienceDirect
Overview of the Mim8 FRONTIER clinical development program
ISTH 2022 – Novo moves forward with its Hemlibra rival - Medical Buyer
Mim8 clinical development program: an overview of the FRONTIER studies
